ArticleFrontiers in oncology2026
The aMAP score improves discrimination of prognostic models in hepatocellular carcinoma after radiofrequency ablation.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The aMAP score has proven a reliable model for predicting the risk of hepatocellular carcinoma (HCC) development in patients with various types of hepatitis, but its value in predicting recurrence in HCC patients after radiofrequency ablation (RFA) remains unclear. This study aims to assess the utility of the aMAP score for predicting recurrence in HCC patients after RFA. Methods: The retrospective analysis included 350 firstly diagnosed HCC patients who underwent RFA. Survival analysis was performed using Kaplan-Meier curves with the log-rank test. Cox regression analysis was conducted to assess the prognostic value of aMAP score. The Fine-Gray method was adopted for sensitivity analysis. Subgroup analyses verified the consistency of the aMAP score's predictive value. C-index, net reclassification improvement (NRI), and integrated discrimination improvement (IDI) were used to evaluate its incremental predictive value. Results: Among 350 patients undergoing RFA, a total of 197 (56.3%) patients had a low aMAP score (≤ 63.55), and 153 patients (43.7%) had a high aMAP score (> 63.55). Patients with low aMAP scores exhibited significantly longer recurrence-free survival (RFS) ( Conclusions: The aMAP score is a potentially predictor for HCC patients undergoing RFA. Incorporation of the aMAP score into the prediction model improved its predictive accuracy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.